News
ADAP
1.105
+9.41%
0.095
Weekly Report: what happened at ADAP last week (0415-0419)?
Weekly Report · 1d ago
Leerink Partners Sticks to Its Hold Rating for Adaptimmune Therapeutics (ADAP)
TipRanks · 1d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Mobile-health Network (NASDAQ:MNDR) shares rose 15.0% to $31.35 during Friday's after-market session. The company's market cap stands at $1.0 billion. China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock moved upwards by 6.7%.
Benzinga · 3d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Adaptimmune Therapeutics (ADAP)
TipRanks · 4d ago
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Adaptimmune Therapeutics plc shares have retraced a considerable 29% in the last month. The share price of the company is down 24% in a year. The company's price-to-sales ratio of 4.5x is lower than the average for its industry. Its low revenue growth is contributing to its low P/S ratio.
Simply Wall St · 04/16 10:11
Maintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration Termination
TipRanks · 04/16 06:56
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
TipRanks · 04/16 06:50
Adaptimmune (ADAP) Down on End of Collaboration With Roche
NASDAQ · 04/15 18:12
Weekly Report: what happened at ADAP last week (0408-0412)?
Weekly Report · 04/15 09:28
Adaptimmune slips as Roche strategic collaboration ends
Healthcare Adaptimmune falls as Roche strategic collaboration ends Apr. 12, 2024. Adaptimmune Therapeutics struck a multi-year strategic collaboration with Roche's Genentech unit in 2021. The agreement aimed at launching cell therapies for various cancer indications using ADAP's allogeneic platform.
Seeking Alpha · 04/12 12:53
Adaptimmune Therapeutics Says On April 10, Unit Of Co, Received Notice Of Termination Of Strategic Collaboration And License Agreement With Genentech; Termination Will Become Effective 180 Days After Date Of Receipt; As Result Of Termination, Co Not Entitled To Receive Further Milestones Or Other Payments Due After Termination Date
Benzinga · 04/12 12:13
ADAPTIMMUNE THERAPEUTICS PLC: WILL ALSO CEASE TO HAVE ANY DEVELOPMENT OBLIGATIONS AFTER TERMINATION DATE
Reuters · 04/12 12:07
ADAPTIMMUNE THERAPEUTICS PLC: TERMINATION WILL BECOME EFFECTIVE 180 DAYS AFTER DATE OF RECEIPT OF NOTICE OF TERMINATION
Reuters · 04/12 12:07
Weekly Report: what happened at ADAP last week (0401-0405)?
Weekly Report · 04/08 09:30
Adaptimmune Therapeutics Plc: [Amend]General statement of acquisition of beneficial ownership
Press release · 04/03 02:06
Weekly Report: what happened at ADAP last week (0325-0329)?
Weekly Report · 04/01 09:30
Adaptimmune Therapeutics (NASDAQ:ADAP) shareholders are up 18% this past week, but still in the red over the last three years
Adaptimmune Therapeutics plc (NASDAQ:ADAP) is up 99% in the last quarter. The share price of the company has dropped 71% over three years. In the last three years, the company saw its revenue grow by 92% per year. The company's share price could be a sign of a turning point for the company. Read on to learn about the 6 warning signs we've spotted with AdaptimmuneTherapeutics.
Simply Wall St · 03/29 10:47
Weekly Report: what happened at ADAP last week (0318-0322)?
Weekly Report · 03/25 09:31
Weekly Report: what happened at ADAP last week (0311-0315)?
Weekly Report · 03/18 09:30
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
TipRanks · 03/13 06:30
More
Webull provides a variety of real-time ADAP stock news. You can receive the latest news about Adaptimmune Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About ADAP
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Company’s most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.